A phase III study to evaluate the long-term safety and efficacy of fasinumab in patients with pain due to osteoarthritis of the knee or hip
AAs and JRs showed a dose relationship to fasinumab and were associated with baseline OA status. Fasinumab achieved statistically significant improvements in WOMAC pain and physical function scores compared with placebo.
Authors
- Christine Winslow
- John D. Davis (ORCID: https://orcid.org/0000-0001-6282-1670)
- Simon Eng (ORCID: https://orcid.org/0009-0001-4964-5729)
- Yamini Patel (ORCID: https://orcid.org/0000-0003-0095-2231)
- Angela Manley
- Jingning Mei
- Paula Dakin (ORCID: https://orcid.org/0000-0002-8925-0414)
- Hazem E. Hassan (ORCID: https://orcid.org/0000-0002-8633-3636)
- Haitao Gao
- Gregory P. Geba (ORCID: https://orcid.org/0000-0001-8936-748X)
- Thomas J. Schnitzer (ORCID: https://orcid.org/0000-0002-4048-5431)
- Ngan Trinh
- Michael R. Fetell (ORCID: https://orcid.org/0000-0002-4607-4334)
- Stephen J. DiMartino (ORCID: https://orcid.org/0009-0001-0592-7644)
- Garen Manvelian
- Ned Braunstein
- K. C. Turner
- Tina Ho
Institutions
- Northwestern University (US)
- Regeneron (United States) (US)
- Teva Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Osteoarthritis and Cartilage Open
- Published
- 2024-10-22
- DOI
- https://doi.org/10.1016/j.ocarto.2024.100533
- Citations
- 9
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 4.23
Funders
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals